ArticleTropical medicine and health2025
Evaluation of the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis in Nairobi, Kenya.
Article in Tropical medicine and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Longitudinal urinary LAM measurements in pulmonary tuberculosis patients: preliminary observations.Tropical medicine and health · 2026Article
- Article
- The PATHFAST TB LAM Ag assay: a validated protocol for quantitative tuberculosis treatment monitoring.Frontiers in antibiotics · 2026Article
- Clinical evaluation of the diagnostic performances and treatment monitoring of the new PATHFAST TB LAM Ag assay in sputum specimens of patients with tuberculosis or with nontuberculous mycobacteria pulmonary disease.Journal of clinical microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTreatment monitoring is important in pulmonary tuberculosis (PTB) management, since prolonged treatment necessitates regular assessments to prevent treatment failure and the emergence of drug-resistant strains. However, the lack of a simple, rapid, and reliable treatment monitoring tool (TMT) remains a major challenge. We evaluated the utility of measuring sputum lipoarabinomannan (LAM) concentration by the PATHFAST TB LAM Ag assay (PHC Corporation, Tokyo, Japan) as a TMT in patients with PTB in Nairobi, Kenya.
methodsWe retrospectively analyzed sputum LAM levels via the PATHFAST TB LAM Ag assay from a Nairobi cohort of patients with PTB and compared these results with conventional microbiological tests (acid-fast bacilli [AFB] smear microscopy; mycobacterial growth indicator tube [MGIT] culture). Stored sputum pellets processed with N-acetyl-L-cysteine (NALC)-NaOH were used for LAM measurement. Serial LAM concentrations measured every 2 weeks over an 8-week period were compared across bacterial load categories to assess correlations with AFB smear grades and culture results using the Kruskal-Wallis and Mann-Whitney U tests.
resultsThe 98 patients included here had a median age of 37 years (Interquartile Range: 27-44). The majority were men (74/98, 75.5%) and the MGIT culture was positive for 89 (90.8%) of them. Patients with elevated baseline LAM concentrations showed a significant reduction in LAM levels with treatment (90% median reduction by week 8), whereas those with low baseline LAM concentrations did not show a declining trend. Sputum LAM levels were significantly higher in culture-positive samples compared to culture-negative samples (23.8 pg/mL vs. 10.8 pg/mL, P < 0.001). Sputum LAM levels showed a significant correlation with AFB smear grades, with median concentrations increasing progressively from 11.3 pg/mL in smear-negative samples to 19.7 pg/mL in scanty/1 + samples, and 46.7 pg/mL in 2 + /3 + samples (P = 0.0001). LAM levels were significantly higher in culture-positive/AFB-positive sputum samples (viable bacilli) than in culture-negative/AFB-positive samples (non-viable bacilli) (P < 0.0001).
conclusionOur findings revealed that sputum LAM concentration declined during TB treatment, particularly among patients with high baseline levels, and correlated with AFB smear grades and culture results. Additionally, LAM concentrations differed between culture-positive and culture-negative samples among AFB smear-positive samples. Further prospective studies are needed to assess LAM levels as a TMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.